Search

everythinglearnresearchcommunity

for

Search:↓

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

A 19-year-old noticed hair thinning and mild receding hairline, opting for a treatment regime excluding finasteride and minoxidil. The regime includes derma rolling, rosemary and coconut oil, a massage comb, a DHT-blocker shampoo, and vitamins B12 and Biotin.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

The conversation discusses using GHK-Cu for hair loss, with one user suggesting subcutaneous administration for better control. The effectiveness of topical application is questioned due to a lack of reliable reviews.

The conversation is about the effectiveness of alfatradiol for hair loss and whether it can be used with or as a replacement for common treatments like minoxidil, finasteride, and RU58841. The user is seeking feedback on others' experiences with alfatradiol.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.

Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.

The conversation discusses the idea of naturally lowering testosterone levels to potentially reduce DHT and help with hair loss, though it is speculative and not tested by the original poster. Participants suggest using treatments like finasteride, dutasteride, or RU58841 instead, as they directly target DHT without reducing testosterone.

The user had a failed hair transplant in 2018, didn't use medication, and experienced severe depression from further hair loss. They started treatment in 2022 with 0.5mg daily finasteride, 2.5mg oral minoxidil, 1ml daily topical minoxidil, and are considering low dose RU58841 and dermarolling.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

The conversation discusses alternatives to Platelet-rich plasma (PRP) for treating androgenic alopecia. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The user underwent a hair transplant in Turkey and has been using a topical solution with 5% minoxidil and 0.0025% finasteride, along with Ket 2% shampoo and derma rolling, to maintain hair status. They are uncertain about improvements, noting thicker non-transplanted hair, and are considering increasing medication frequency to enhance results.

The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

OP believes RU58841 affected their thyroid, causing hypothyroidism and impacting minoxidil's effectiveness. They plan to start thyroid medication to improve hair regrowth.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Han Bio claims success in hair multiplication using dermal papilla cells. Treatments discussed include Minoxidil, finasteride, and RU58841.

Hair loss discussion includes DIY HMI-115 and its high cost (20-30k per person). Minoxidil, finasteride, and RU58841 mentioned as treatments.

The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.

A 25-year-old male experienced noticeable temple regrowth using 1mg finasteride, 2.5mg oral minoxidil, and 2mg GHK-Cu over three months. The user is pleased with the progress, especially on the left temple.

The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgen receptors, and Minoxidil as a vasodilator for hair growth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.

The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.

The conversation discusses reducing scalp DHT to prevent hair loss, with a focus on using dutasteride, finasteride, and other treatments like RU58841 and minoxidil. It highlights the challenges of managing hair loss while on high testosterone levels, suggesting that dutasteride may be more effective than finasteride in such cases.

The user experienced side effects from a hair loss treatment and is considering using pyrilutamide, alfatradiol, and possibly minoxidil. They are unsure about starting minoxidil immediately or waiting to see the effects of the other treatments.